Anat Loewenstein, MD, presented real-world results of remote imaging at the International SPECTRALIS Symposium

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Dr Brunstetter, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, delivered the lecture at this year's ISS alongside his colleague Warren Hoburg

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

Prof Malik shared his presentation, titled "An eye on neurodegenerative diseases: Challenging the dogma," at this year's International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

More than 35 lectures across seven topics, plus a keynote address, will be featured during the meeting

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

Special programming for young ophthalmologists will be hosted in the YO lounge

This year’s multi-specialty programme features the SOE Leadership Development Programme (EuLDP), the International Society of Ocular Trauma (ISOT), European University Professors of Ophthalmology (EUPO) and more

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.